Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +220.00p +4.36% 5,270.00p 5,240.00p 5,300.00p 5,270.00p 5,110.00p 5,130.00p 92,906 16:12:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 178.6 -39.6 -31.8 - 3,506.27

Hutchison China Meditech Share Discussion Threads

Showing 1801 to 1825 of 1825 messages
Chat Pages: 73  72  71  70  69  68  67  66  65  64  63  62  Older
DateSubjectAuthorDiscuss
13/12/2018
14:13
agreed Lauders, there was also a dosing issue recently with 523 but that was not reported presumably because it's midway through. We certainly need progress now as approval of the Fruquintinib NDA in September resulted in no reaction from the market.
nerdofsteel
13/12/2018
12:38
Just hoping one or both are not as disappointing as the FALUCA results NofS. That would be a big disappointment and we would no doubt be knocked back quite a bit.
lauders
13/12/2018
11:38
The big one is Savolitinib, especially these......... Initiate global study of savolitinib/ Tagrisso® combo in 2L/3L NSCLC post Tagrisso® failure; AZ presents data on c-Met resistance; regulatory dialogue; Molecular epidemiology study (n>200) in PRCC [3] – possibly BTD enabling. We can expect news on both of these studies in the next 2 weeks ;o-)
nerdofsteel
13/12/2018
08:12
Still at a £1+ discount to the US share price.
nhb001
13/12/2018
07:21
chartwise, looks like this is making a nice bowl
mad foetus
13/12/2018
01:56
Hoping for a great day here when the UK market opens for business. Up around 9% in the USA at close of play yesterday and if HCM happen to release a positive Thursday RNS it could really be a great day!
lauders
06/12/2018
10:00
This is probably not helping at the moment - significant price pressure in Chian on drugs, mainly generics, but the entire sector is being hit. U.S Investor sentiment against China Co's also likely to increase as the CFO of Huawei has just been arrested in Canada and the U.S request extradition. https://uk.finance.yahoo.com/news/china-apos-drugmakers-plunge-most-091532399.html
nerdofsteel
05/12/2018
10:39
Good point on NASDAQ Sportii, thanks for that information
nerdofsteel
05/12/2018
09:06
As long as the share price stays above 50 GBP, it shouldn’t be matter of concern. We have seen on a number of times share price bouncing back. (Not sure it would happen today, as Nasdaq closed today in respect of president Bush?) Recent announcement of multiple collaborations is indeed quite remarkable. Out of curiosity, I checked INNOVENT side of news. I found “global” term very interesting. ‘Innovent Announces Global Collaboration with Hutchison MediPharma to Evaluate Combination of Sintilimab and Fruquintinib in Solid Tumors’ GLA.
sportii
05/12/2018
08:08
True! Yesterday was carnage in U.S markets, especially the Pharma and Biotech sectors so his chart and the golden cross technicals wouldn't have worked. It'll probably bounce today!
nerdofsteel
04/12/2018
16:40
That Andreas guy on stocktwits - he's a curse. He goes short and we rally, now he's long and we drop over 5%. I think he did the same on Beigene!?
samsj
04/12/2018
00:45
Thanks for the link NofS. I guess you will have more funds to use to get you nearer to your 20,000 holding now that an offer has been made for TSRO. With luck the "talent, energy, and hunger" mentioned in this piece from your link will pay-off handsomely in a few years: While Chi-Med began by building a team of returnees, it has in turn begun to train a pool of local talent. Today, 80 percent of its workers are locally educated. “[Companies] need to tap into the deep reservoir of intellect that exists here,” said CEO Hogg. “China is one of the most enterprising business environments that you’re going to come across. There’s a lot of talent, energy, and hunger.” Https://www.statnews.com/2018/12/03/pharma-valley-chinas-kendall-square/
lauders
03/12/2018
17:21
Nice offer from Glaxo for my TSRO stock!
nerdofsteel
03/12/2018
17:21
Nice article from today's Statnews on China's Pharma valley which includes comments from Chi-Med's CEO hxxps://www.statnews.com/2018/12/03/pharma-valley-chinas-kendall-square/
nerdofsteel
03/12/2018
16:06
10:03 ET - GlaxoSmithKline falls more than 7% on the New York Stock Exchange after announcing the purchase of a cancer biotech. Glaxo says it will pay $5.1B for Tesaro, which sells a cancer drug, named Zejula, for treatment of ovarian cancer. The deal helps Glaxo gain a foothold in the lucrative cancer-drugs market. But Zejula's sales have lagged other drugs in its class, known as Parp inhibitors, notably AstraZeneca's Lynparza. And doctors and industry officials say Zejula's side-effect profile is worse than other Parps. (jonathan.rockoff@wsj.com; @jonathanrockoff)(END) Dow Jones NewswiresCan't hurt credibility,Glaxo paying up .
steeplejack
03/12/2018
11:25
Well done NofS. Impressive investment/outlay so hope it all goes to plan. Good luck.
lauders
03/12/2018
10:39
Just made another purchase......ultimate goal is to get back to the 20,000 holding I had 10 years ago
nerdofsteel
01/12/2018
11:08
That will be the MCI tracker funds buying. It looks like lots of holders have sold into that. The buying may stop now that 30 November is passed.
nhb001
01/12/2018
10:59
Lots sold but charts are very bullish at the moment with hammer candlestick
nerdofsteel
30/11/2018
22:31
Question is where did all that stock come from without driving the price up more?
dbadvn
30/11/2018
22:16
6.03 million ADR's traded on NASDAQ today, circa $207m worth of stock. That is unprecedented, I do not recall seeing that level of trading since the first IPO.
nerdofsteel
29/11/2018
22:57
Thanks for your LSE post here too NofS. The Taizhou link worked fine at home so nice to see 3x websites working.
lauders
29/11/2018
16:33
Great work Lauders and to add, here's my LSE post from this morning:- 1. Shanghai Junshi appears to be in the process of a HK IPO 2. Innovent Biologics - IPO'd in HK in early Nov 3. Taizhou Hanzhong Pharmaceuticals - private 4. Genor Biopharma - private (majority owned buy Hill House Capital)
nerdofsteel
29/11/2018
11:34
Some news arrived anyway and it is all adding to the build blocks of the future. If any of these collaborations produce anything really meaningful it will just add more value to HCM than we believe at possible at present. Not too impressed that Shanghai Junshi Biosciences Co. Ltd's website doesn't seem to open for me. Found this though: Http://www.hkexnews.hk/APP/SEHK/2018/2018080501/Documents/SEHK201808060017.pdf Will take some reading! Innovent Biologics (Suzhou) Co. Ltd's website looks more promising! Http://innoventbio.com/en/#/ Will have to try the link for Taizhou Hanzhong Pharmaceuticals, Inc again at home. Doesn't want to open for me at the moment: Http://www.tianruipharm.com/ Genor Biopharma Co. Ltd's website looks more promising: Http://www.genorbio.com/en/ So two hits and two misses re: websites. Perhaps a bit like the chances of success with the collaboration efforts?
lauders
29/11/2018
08:03
Cheeky timing!
mad foetus
Chat Pages: 73  72  71  70  69  68  67  66  65  64  63  62  Older
Your Recent History
LSE
HCM
Hutchison ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181215 01:09:03